Inhibrx Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Inhibrx Biosciences
INBX Stock  USD 83.91  2.38  2.92%   
Inhibrx Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Inhibrx Biosciences' valuation are provided below:
Gross Profit
-171.8 M
Market Capitalization
486.9 M
Enterprise Value Revenue
305.8238
Revenue
1.4 M
Earnings Share
(16.57)
We have found one hundred twenty available fundamental trends for Inhibrx Biosciences, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Inhibrx Biosciences regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to drop to about 85.6 M in 2026

Inhibrx Biosciences Total Revenue

171,000

Check Inhibrx Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Selling General Administrative of 154.4 M or Selling And Marketing Expenses of 202.4 K, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0522 or PTB Ratio of 1.58. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Inhibrx Stock
Check out the analysis of Inhibrx Biosciences Correlation against competitors.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx Biosciences guide.

Inhibrx Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets140.4 M207.9 M95.6 M
Slightly volatile
Short and Long Term Debt Total8.8 M9.3 M44.2 M
Slightly volatile
Other Current Liabilities36.1 M34.4 M11.6 M
Slightly volatile
Total Current Liabilities28 M46.8 M19.8 M
Slightly volatile
Property Plant And Equipment Net8.2 M15.6 M5.6 M
Slightly volatile
Accounts Payable7.5 M10.6 M4.8 M
Slightly volatile
Cash123.6 M175.5 M84.2 M
Slightly volatile
Non Current Assets Total24.6 M23.4 M8.1 M
Slightly volatile
Cash And Short Term Investments123.6 M175.5 M84.2 M
Slightly volatile
Common Stock Shares Outstanding12.4 M13 M31.7 M
Slightly volatile
Liabilities And Stockholders Equity140.4 M207.9 M95.6 M
Slightly volatile
Non Current Liabilities Total7 M7.4 M48.9 M
Slightly volatile
Other Current Assets8.1 M8.5 M11.2 M
Pretty Stable
Total Liabilities51.5 M54.3 M69.7 M
Slightly volatile
Total Current Assets130.1 M184.5 M88.3 M
Slightly volatile
Short Term Debt2.6 M1.4 M3.4 M
Slightly volatile
Current Deferred Revenue141.9 K149.4 K2.1 M
Slightly volatile
Net Receivables477.2 K378 K617.6 K
Slightly volatile
Non Currrent Assets Other8.2 M7.9 M2.8 M
Slightly volatile
Common Stock1.1 K1.1 K2.9 K
Pretty Stable
Capital Lease Obligations6 M9.3 M5.4 M
Slightly volatile
Property Plant And Equipment Gross18.8 M25.8 M14.6 M
Slightly volatile
Long Term Debt165.6 M186.3 M203.3 M
Slightly volatile
Capital Stock8559004.3 K
Slightly volatile

Inhibrx Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.3 M2.6 M954.2 K
Slightly volatile
Selling General Administrative154.4 M147.1 M31.1 M
Slightly volatile
Selling And Marketing Expenses202.4 K227.7 K248.5 K
Slightly volatile
Total Revenue171 K180 K5.6 M
Slightly volatile
Other Operating Expenses400.5 M381.4 M110.5 M
Slightly volatile
Research Development246 M234.3 M79.7 M
Slightly volatile
Cost Of Revenue2 M2.1 M24.7 M
Very volatile
Total Operating Expenses397.7 M378.8 M99.2 M
Slightly volatile
Interest Expense11.9 M15.5 M7.6 M
Slightly volatile
Tax Provision2.1 K1.8 K2.8 K
Slightly volatile
Reconciled Depreciation1.7 M2.6 M1.4 M
Slightly volatile
Interest Income9.1 M9.8 M11.6 M
Slightly volatile

Inhibrx Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation70.7 M67.3 M16.1 M
Slightly volatile
Begin Period Cash Flow335.6 M319.6 M93 M
Slightly volatile
Other Cashflows From Financing Activities92.1 M82.4 M64.8 M
Slightly volatile
Depreciation2.8 M2.6 M959.5 K
Slightly volatile
Capital Expenditures1.8 M3 M1.2 M
Slightly volatile
Total Cash From Financing Activities107.7 M82.4 M73.2 M
Slightly volatile
End Period Cash Flow123.6 M175.5 M84.2 M
Slightly volatile
Dividends Paid881.2 K745.2 K1.1 M
Slightly volatile
Other Cashflows From Investing Activities44 K49.5 K54 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.1 K1 K349
Slightly volatile
Dividend Yield0.05220.04970.0267
Slightly volatile
Days Sales Outstanding724690162
Slightly volatile
Stock Based Compensation To Revenue27626350.562
Slightly volatile
Capex To Depreciation1.891.311.3995
Slightly volatile
EV To Sales213353214
Slightly volatile
Payables Turnover0.270.2846.209
Slightly volatile
Sales General And Administrative To Revenue604576109
Slightly volatile
Research And Ddevelopement To Revenue963917182
Slightly volatile
Capex To Revenue12.2711.692.4013
Slightly volatile
Cash Per Share9.969.493.2918
Slightly volatile
Days Payables Outstanding1.4 K1.3 K531
Slightly volatile
Current Ratio3.243.543.9078
Pretty Stable
Receivables Turnover0.520.559.667
Slightly volatile
Graham Number124140153
Slightly volatile
Capex Per Share0.170.160.0524
Slightly volatile
Revenue Per Share0.01510.01590.1712
Slightly volatile
Interest Debt Per Share1.681.341.4743
Slightly volatile
Debt To Assets0.04860.05120.6989
Slightly volatile
Days Of Payables Outstanding1.4 K1.3 K531
Slightly volatile
Quick Ratio3.583.544.1481
Pretty Stable
Net Income Per E B T0.760.90.828
Slightly volatile
Cash Ratio3.073.373.7499
Pretty Stable
Days Of Sales Outstanding724690162
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.171.0385
Slightly volatile
Fixed Asset Turnover0.01610.0173.7993
Slightly volatile
Debt Ratio0.04860.05120.6989
Slightly volatile
Price Sales Ratio1.1 K1 K349
Slightly volatile
Asset Turnover0.00120.00130.2296
Slightly volatile

Inhibrx Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap243.5 M256.4 M538.6 M
Slightly volatile
Enterprise Value85.6 M90.1 M481.9 M
Slightly volatile

Inhibrx Fundamental Market Drivers

Inhibrx Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Inhibrx Biosciences Financial Statements

Inhibrx Biosciences investors use historical fundamental indicators, such as Inhibrx Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue149.4 K141.9 K
Total Revenue180 K171 K
Cost Of Revenue2.1 M2 M
Stock Based Compensation To Revenue 263.33  276.50 
Sales General And Administrative To Revenue 575.57  604.35 
Research And Ddevelopement To Revenue 916.84  962.69 
Capex To Revenue 11.69  12.27 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue-1.9 K-1.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx Biosciences' price analysis, check to measure Inhibrx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx Biosciences is operating at the current time. Most of Inhibrx Biosciences' value examination focuses on studying past and present price action to predict the probability of Inhibrx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx Biosciences' price. Additionally, you may evaluate how the addition of Inhibrx Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY